Company
Clinical-stage genetic medicines company developing gene therapies for inherited cardiomyopathies, using a mechanobiology approach that targets the mechanical stress signalling inside failing heart muscle cells rather than correcting the mutated gene directly. Lead asset NVC-001 is an AAV-delivered therapy for LMNA-related dilated cardiomyopathy, an aggressive genetic heart-muscle disease with no targeted treatment. Longevity relevance is disease-specific rather than general: it aims to halt progression of a condition that causes heart failure and early death in carriers, not to modify ageing biology broadly. Both Singapore HQ and incorporation as a Pte Ltd confirmed on the company site, so it meets limb (b) of the inclusion rule.
Thesis
Market data
| Metric | Detail |
|---|---|
| Exchange | Unlisted |
| Ticker | None |
| Secondary listing | None |
| Market cap | Not disclosed |
| Status | Private |
Get in touch
Offering
No commercial services are recorded for this company yet.
People
variis does not publish portraits of named individuals without a licence to do so.
Recent inflection
On 10 June 2025 the company announced FDA clearance of its IND for NVC-001 in LMNA-related dilated cardiomyopathy, clearing the way for first-in-human clinical work. This followed the close of a US$45m Series B on 6 May 2025 raised to fund that clinical development, per the company's own newsroom (https://www.nuevocor.com/news).
Keep reading
Sources
Every entity profile on variis is sourced. Not investment advice.